Deals Report

February 2025

VENIONAIRE DEALMATRIX

Deals Report

February 2025

Overview

February 2025 marked a pivotal moment in the European startup ecosystem, revealing clear patterns of investor confidence amid evolving market dynamics. The data, gathered from Crunchbase, shows a compelling story of where capital is flowing and which innovations are capturing investor imagination.

Artificial Intelligence continues to be the focal point of European innovation funding, attracting a significant share of available capital. Its dominance isn't just about scale—it's strategically allocated across different funding stages. While many AI startups secure early Pre-Seed investment, a strong pipeline advances to the Seed stage, reflecting investor confidence in their growth potential.

Jacopo Binati
Analyst @ Venionaire Capital

Deals Report
February 2025

AI: The European Funding Cornerstone



Table 1: Main Industries by Funding Rounds

Artificial Intelligence remains the cornerstone of European innovation funding, commanding an outsized portion of available capital. This dominance isn't merely about quantity—it's **strategically distributed across the funding lifecycle**. While numerous AI startups secure early Pre-Seed capital, a healthy portion progresses to Seed stage, indicating investor confidence in their journey.

What's particularly telling is how **AI's gravitational pull affects adjacent sectors**. Health Care, Biotech, and Information Technology startups incorporating AI capabilities are witnessing accelerated funding trajectories, while more traditional healthcare ventures face a steeper climb. This suggests **investors are betting on the convergence of AI** with domain-specific expertise rather than conventional approaches.

Deals Report
February 2025

The Early-Stage Funding Renaissance



Table 2: Main Funding Rounds

February's funding composition reveals a **striking emphasis on early-stage investments**, **with Seed funding capturing 33.5% of all deals**. When combined with Pre-Seed (13.45%) and Series A (13.69%), early-stage investments account for over 60% of the month's activity. This represents a tactical shift from previous quarters, where later-stage funding had seen temporary prioritization.

This recalibration toward early-stage investments signals **investor intent to build new pipelines of innovation**, particularly as previous cohorts of startups either find sustainable paths forward or face consolidation. The relatively modest showing of Series C+ rounds (collectively under 5%) further suggests a widening "middle-stage gap" that maturing startups must navigate.

Deals Report
February 2025

The Emergence of New Leaders



Table 3: Money raised by Company

Eclairion's exceptional $160 million raise exemplifies a new breed of European startup—**one built from inception with global ambitions.** Their success, alongside OrganOx and Solaris, demonstrates that **European startups can now secure nine-figure rounds** without necessarily relocating to the US, a significant evolution from previous years. The significant gap between these leaders and the remainder of funded companies reveals a **"winner-takes-most" dynamic** forming in key sectors.

Companies securing top-tier funding are capturing disproportionate market share, talent, and subsequent investment opportunity, **potentially accelerating toward market dominance** while others struggle to maintain momentum through the "valley of death" between early validation and scaled commercialization.

Deals Report
February 2025

Geographic Concentration and Capital Efficiency



Table 4: Money raised by Country

The **United Kingdom's commanding lead**—**nearly $800 million raised** across all stages—underscores London's enduring position as Europe's startup capital. However, a deeper analysis of Germany's and France's performances reveals noteworthy efficiency metrics. German startups, while raising less total capital than their UK counterparts, appear to be converting funding into revenue more efficiently, particularly in B2B and manufacturing sectors.

The stark funding dropoff beyond the top three markets highlights **ongoing challenges in pan-European scaling**. Switzerland stands as the exception, demonstrating how specialized expertise (particularly in deep tech and biotech) can enable smaller ecosystems to punch above their weight.